For PIK3CA mutant subjects, 79.4% were ER+ and this mutation was observed in nearly 40 % of Group 1A patients, indicating that PIK3CA may be an earlier driver for hormone responsive breast cancer during oncogenesis. This evidence concerns the gene ESR1 and breast carcinoma.